6. Clinical benefit table. Artz versus Hylan G‐F 20. Dichotomous outcome measure.

Study	Time	Treatment	Outcome	No. improved	No. of pts	Risk (%)	Risk difference	NNT
Karlsson 2002c	14‐26 wk	E: Artzal	Number of clinical failures	2	90	2	‐5	20
		C: Hylan G‐F 20		6	86	7
Karlsson 2002c	14‐26 wk	E: Artzal	Number of survivors	39	90	43	‐1	100
		C: Hylan G‐F 20		38	86	44
Karlsson 2002c	45‐52 wk	E: Artzal	Number of clinical failures	26	66	39	‐7	14.3
		C: Hylan G‐F 20		32	70	46